請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/63218
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 張上淳 | |
dc.contributor.author | Ko-Hsin Chen | en |
dc.contributor.author | 陳可欣 | zh_TW |
dc.date.accessioned | 2021-06-16T16:28:53Z | - |
dc.date.available | 2018-03-04 | |
dc.date.copyright | 2013-03-04 | |
dc.date.issued | 2013 | |
dc.date.submitted | 2013-01-07 | |
dc.identifier.citation | 1. Hsueh PR, Hoban DJ, Carmeli Y, et al. Consensus review of the epidemiology and appropriate antimicrobial therapy of complicated urinary tract infections in Asia-Pacific region. J Infect 2011;63:114-23.
2. Gupta K, Hooton TM, Naber KG, et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis 2011;52:e103-20. 3. Grabe M, Bishop M, Bjerklund-Johansen T, et al. Guidelines on urological infections. European association of urology 2009:1-110. 4. Guidelines for antimicrobial therapy of urinary tract infections in Taiwan. Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi 2000;33:271-2. 5. Abrahamian FM, Moran GJ, Talan DA. Urinary tract infections in the emergency department. Infect Dis Clin North Am 2008;22:73-87, vi. 6. Khawcharoenporn T, Vasoo S, Ward E, Singh K. High rates of quinolone resistance among urinary tract infections in the ED. Am J Emerg Med 2012;30:68-74. 7. Wright SW, Wrenn KD, Haynes M, Haas DW. Prevalence and risk factors for multidrug resistant uropathogens in ED patients. Am J Emerg Med 2000;18:143-6. 8. Zhanel GG, Hisanaga TL, Laing NM, et al. Antibiotic resistance in Escherichia coli outpatient urinary isolates: final results from the North American Urinary Tract Infection Collaborative Alliance (NAUTICA). Int J Antimicrob Agents 2006;27:468-75. 9. Aguilar-Duran S, Horcajada JP, Sorli L, et al. Community-onset healthcare-related urinary tract infections: comparison with community and hospital-acquired urinary tract infections. J Infect 2012;64:478-83. 10. Foxman B. Epidemiology of urinary tract infections: incidence, morbidity, and economic costs. Am J Med 2002;113 Suppl 1A:5S-13S. 11. Coyle EA, Prince RA. Urinary tract infection. In: DiPiro JT, ed. Pharmacotherapy : a pathophysiologic approach. New York: McGraw-Hill Medical; 2008. 12. Stamm WE. Criteria for the diagnosis of urinary tract infection and for the assessment of therapeutic effectiveness. Infection 1992;20 Suppl 3:S151-4; discussion S60-1. 13. Johansen TE, Botto H, Cek M, et al. Critical review of current definitions of urinary tract infections and proposal of an EAU/ESIU classification system. Int J Antimicrob Agents 2011;38 Suppl:64-70. 14. Ronald A. The etiology of urinary tract infection: traditional and emerging pathogens. Dis Mon 2003;49:71-82. 15. Fish DN. Urinary tract infections. In: Koda-Kimble MA, Young LY, Alldredge BK, et al., eds. Applied Therapeutics: The Clinical Use Of Drugs, 9th Edition. Philadelphia, PA: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2009. 16. Paterson DL. 'Collateral damage' from cephalosporin or quinolone antibiotic therapy. Clin Infect Dis 2004;38 Suppl 4:S341-5. 17. Huang ES, Stafford RS. National patterns in the treatment of urinary tract infections in women by ambulatory care physicians. Arch Intern Med 2002;162:41-7. 18. Czaja CA, Scholes D, Hooton TM, Stamm WE. Population-based epidemiologic analysis of acute pyelonephritis. Clin Infect Dis 2007;45:273-80. 19. Taur Y, Smith MA. Adherence to the Infectious Diseases Society of America guidelines in the treatment of uncomplicated urinary tract infection. Clin Infect Dis 2007;44:769-74. 20. Martinez MA, Inglada L, Ochoa C, Villagrasa JR. Assessment of antibiotic prescription in acute urinary tract infections in adults. J Infect 2007;54:235-44. 21. Caterino JM, Weed SG, Espinola JA, Camargo CA, Jr. National trends in emergency department antibiotic prescribing for elders with urinary tract infection, 1996-2005. Acad Emerg Med 2009;16:500-7. 22. Jan IS, Cheng SH, Hsu HC, Hsueh PR. Physicians' adherence to guidelines for empirical treatment of urinary tract infection in Taiwan. Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi 2007;40:532-6. 23. Johnson L, Sabel A, Burman WJ, et al. Emergence of fluoroquinolone resistance in outpatient urinary Escherichia coli isolates. Am J Med 2008;121:876-84. 24. Talan DA, Krishnadasan A, Abrahamian FM, Stamm WE, Moran GJ. Prevalence and risk factor analysis of trimethoprim-sulfamethoxazole- and fluoroquinolone-resistant Escherichia coli infection among emergency department patients with pyelonephritis. Clin Infect Dis 2008;47:1150-8. 25. van der Starre WE, van Nieuwkoop C, Paltansing S, et al. Risk factors for fluoroquinolone-resistant Escherichia coli in adults with community-onset febrile urinary tract infection. J Antimicrob Chemother 2010;66:650-6. 26. Lim SK, Park IW, Lee WG, Kim HK, Choi YH. Change of antimicrobial susceptibility among Escherichia coli strains isolated from female patients with community-onset acute pyelonephritis. Yonsei Med J 2012;53:164-71. 27. Ha YE, Kang CI, Joo EJ, et al. Clinical implications of healthcare-associated infection in patients with community-onset acute pyelonephritis. Scand J Infect Dis 2011;43:587-95. 28. McCabe WR, Jackson GG. Treatment of Pyelonephritis: Bacterial, Drug and Host Factors in Success or Failure among 252 Patients. N Engl J Med 1965;272:0137-44. 29. Frimodt-Moller N. Correlation between pharmacokinetic/pharmacodynamic parameters and efficacy for antibiotics in the treatment of urinary tract infection. Int J Antimicrob Agents 2002;19:546-53. 30. Raz R, Okev N, Kennes Y, Gilboa A, Lavi I, Bisharat N. Demographic characteristics of patients with community-acquired bacteriuria and susceptibility of urinary pathogens to antimicrobials in northern Israel. The Israel Medical Association journal : IMAJ 2000;2:426-9. 31. Raz R, Chazan B, Kennes Y, et al. Empiric use of trimethoprim-sulfamethoxazole (TMP-SMX) in the treatment of women with uncomplicated urinary tract infections, in a geographical area with a high prevalence of TMP-SMX-resistant uropathogens. Clin Infect Dis 2002;34:1165-9. 32. McNulty CA, Richards J, Livermore DM, et al. Clinical relevance of laboratory-reported antibiotic resistance in acute uncomplicated urinary tract infection in primary care. J Antimicrob Chemother 2006;58:1000-8. 33. Talan DA, Stamm WE, Hooton TM, et al. Comparison of ciprofloxacin (7 days) and trimethoprim-sulfamethoxazole (14 days) for acute uncomplicated pyelonephritis pyelonephritis in women: a randomized trial. JAMA 2000;283:1583-90. 34. Harbarth S, Garbino J, Pugin J, Romand JA, Lew D, Pittet D. Inappropriate initial antimicrobial therapy and its effect on survival in a clinical trial of immunomodulating therapy for severe sepsis. Am J Med 2003;115:529-35. 35. Kollef MH. Inadequate antimicrobial treatment: an important determinant of outcome for hospitalized patients. Clin Infect Dis 2000;31 Suppl 4:S131-8. 36. Hyle EP, Lipworth AD, Zaoutis TE, Nachamkin I, Bilker WB, Lautenbach E. Impact of inadequate initial antimicrobial therapy on mortality in infections due to extended-spectrum beta-lactamase-producing enterobacteriaceae: variability by site of infection. Arch Intern Med 2005;165:1375-80. 37. Peralta G, Sanchez MB, Garrido JC, et al. Impact of antibiotic resistance and of adequate empirical antibiotic treatment in the prognosis of patients with Escherichia coli bacteraemia. J Antimicrob Chemother 2007;60:855-63. 38. Lee SS, Kim Y, Chung DR. Impact of discordant empirical therapy on outcome of community-acquired bacteremic acute pyelonephritis. J Infect 2011;62:159-64. 39. Efstathiou SP, Pefanis AV, Tsioulos DI, et al. Acute pyelonephritis in adults: prediction of mortality and failure of treatment. Arch Intern Med 2003;163:1206-12. 40. Pertel PE, Haverstock D. Risk factors for a poor outcome after therapy for acute pyelonephritis. BJU Int 2006;98:141-7. 41. Sobel JD, Kaye D. Urinary Tract Infections. In: Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas, and Bennett's principles and practice of infectious diseases. Philadelphia, PA: Churchill Livingstone/Elsevier; 2010:957-85. 42. Rubin RH, Shapiro ED, Andriole VT, Davis RJ, Stamm WE. Evaluation of new anti-infective drugs for the treatment of urinary tract infection. Infectious Diseases Society of America and the Food and Drug Administration. Clin Infect Dis 1992;15 Suppl 1:S216-27. 43. Warren JW, Abrutyn E, Hebel JR, Johnson JR, Schaeffer AJ, Stamm WE. Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Infectious Diseases Society of America (IDSA). Clin Infect Dis 1999;29:745-58. 44. Hooton TM, Stamm WE. Diagnosis and treatment of uncomplicated urinary tract infection. Infect Dis Clin North Am 1997;11:551-81. 45. Hooton TM, Bradley SF, Cardenas DD, et al. Diagnosis, prevention, and treatment of catheter-associated urinary tract infection in adults: 2009 International Clinical Practice Guidelines from the Infectious Diseases Society of America. Clin Infect Dis 2010;50:625-63. 46. Nicolle LE, Bradley S, Colgan R, Rice JC, Schaeffer A, Hooton TM. Infectious Diseases Society of America guidelines for the diagnosis and treatment of asymptomatic bacteriuria in adults. Clin Infect Dis 2005;40:643-54. 47. Kauffman CA, Fisher JF, Sobel JD, Newman CA. Candida urinary tract infections--diagnosis. Clin Infect Dis 2011;52 Suppl 6:S452-6. 48. Friedman ND, Kaye KS, Stout JE, et al. Health care--associated bloodstream infections in adults: a reason to change the accepted definition of community-acquired infections. Ann Intern Med 2002;137:791-7. 49. Valles J, Calbo E, Anoro E, et al. Bloodstream infections in adults: importance of healthcare-associated infections. J Infect 2008;56:27-34. 50. Annane D, Bellissant E, Cavaillon JM. Septic shock. Lancet 2005;365:63-78. 51. Jeon JH, Kim K, Han WD, et al. Empirical use of ciprofloxacin for acute uncomplicated pyelonephritis caused by Escherichia coli in communities where the prevalence of fluoroquinolone resistance is high. Antimicrob Agents Chemother 2012;56:3043-6. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/63218 | - |
dc.description.abstract | 研究背景:
泌尿道感染為最常見之感染症之ㄧ。美國與歐洲已發表相關之治療指引,2000年臺灣感染症醫學會也針對臺灣之泌尿道感染制定治療準則,然而與國外之建議多有出入。另一方面,菌種抗藥性比例的上升以及各種醫療照護相關感染的出現,使得病人較容易接受不適當的抗生素治療,導致治療的失敗。此外,急診病人具有某些與門診病人不同之特性,但針對急診泌尿道感染之研究並不多。為了提供臨床上適合於急診泌尿道感染病人之使用抗生素選擇的參考依據,進一步以急診病人作為研究群族是必要的。 研究目的: 分析臺大醫院急診部對於泌尿道感染病人治療,所使用之經驗性抗生素處方型態、致病菌種分布與抗生素敏感性試驗結果,並進一步探討治療結果、比較社區型與醫療照護型感染之差別,最後探討治療失敗之相關因子,以期能找出合理且適合於急診病人使用之經驗性抗生素。 研究方法: 本研究為病歷回溯性研究,研究之病人族群為大於或等於20歲,於2011年3月至5月間曾於臺大醫院急診部就診,經診斷碼且進一步篩選後確認為泌尿道感染,並使用抗生素治療者。紀錄並分析醫師之處方型態、菌種培養結果及抗生素敏感性試驗結果,並比較社區型感染與醫療照護相關型感染於菌種分布及抗生素抗藥性之差別。治療結果以第三天(Day 3, D3)、第七天(Day7, D7) 以及療程結束時(end of therapy, EOT) 之臨床治療反應評估。比較使用不同經驗性抗生素以及使用適當的經驗性抗生素與否之治療結果。最後分析第D3治療失敗之相關因子及cefazolin抗藥性之危險因子。 研究結果: 本研究共收入424人,其中急診返家者為242人,急診住院者為182人。醫師之經驗性抗生素處方中,54%為第一代cephalosporins,19.3%為第二代cephalosporins。急診返家病人中,醫師最常處方cephalexin三天療程;急診住院病人中,醫師最常處方cefazolin治療,然而使用cefazolin的病人,醫師最容易因推定失敗 (含細菌培養結果為cefazolin抗藥之菌種) 而換藥。若病人年齡較大、為醫療照護型感染或複雜型感染、有慢性腎臟病、懷疑合併肺炎或蜂窩性組織炎時醫師可能會優先考慮選用cefazolin及cefmetazole以外的抗生素。 醫療照護相關型感染Escherichia coli比例較社區型感染為低 (41.0% vs 66.1%, p<0.0001),但感染Pseudomonas aeruginosa (16.7% vs 1.3%, p<0.0001) 與yeast (5.1% vs 0.4%, p=0.0145) 之比例較高。醫療照護相關型感染之菌株在amoxicillin/clavulanate、cefmetazole、cefotaxime、 gentamicin、cefepime、ceftazidime、levofloxacin的抗藥性比例較高。然而兩組病人在D3、D7、EOT之治療結果無顯著差別。 雖然菌株對cefazolin之抗藥性達72%,但使用cefazolin或cefmetazole或其他抗生素作為經驗性抗生素,在D3、D7、EOT之治療結果無顯著差別;使用不適當經驗性抗生素治療的病人,在D3治療成功的比例較低 (51.7% vs 76.4%, p=0.0215),有70%的病人因治療效果不佳或於得知敏感性試驗結果後換藥,於D7與EOT之治療結果與使用適當經驗性抗生素者無差別。 病人於D3治療失敗的顯著相關因子為阻塞性尿路疾病 (OR=4.395, p=0.0129)、不適當的經驗性抗生素 (OR=4.624, p=0.0126) 及三天內因為推定失敗而換藥(OR=7.051,p<0.0001)。對cefazolin抗藥性之危險因子為存在泌尿道系統外來裝置(OR=10.549, p=0.0223) 或於前一個月使用過第一代cephalosporins (Chi-square, p=0.0221)。 結論: 本研究顯示使用不同經驗性抗生素做治療無顯著差別,推論至急診就醫之病人,可使用cefazolin作為第一線經驗性抗生素治療。但本研究顯示不適當的經驗性抗生素治療會造成早期治療的失敗,因此若病人存在有cefazolin抗藥性菌種之危險因子,如泌尿道系統外來裝置或於前一個月使用過第一代cephalosporins,可考慮使用第二代cephalosporins為第一線治療,以提早讓病人症狀獲得改善。 | zh_TW |
dc.description.abstract | Background:
Urinary tract infection (UTI) is one of the most common infections. Some treatment guidelines for UTI have already been published by American and European associations. In 2000, The Infectious Diseases Society of Taiwan published guidelines for antimicrobial therapy of UTI in Taiwan, but there are some discrepancies between the recommendations of these guidelines. On the other hand, the increasing resistance of the etiological pathogens and the emergence of healthcare-associated infections may lead to inappropriate antibiotic treatment and treatment failure. Furthermore, there are some significant differences in characteristics and UTI management between outpatients and patients in emergency room (ER), but research in ER patients are rare. So it is crucial to conduct a research of antibiotic treatment of UTI in ER patients. Objectives: The aims of this study were to describe the prescription pattern of empirical antibiotics, distribution of the etiological pathogens and their antibiotic resistant rate for UTI patients visiting ER.We also evaluated the treatment outcome of the empirical antibiotic therapy, compared the differences between community-acquired (CA) and healthcare-associated (HCA) UTI, and tried to identify the risk factors for treatment failure. Our final goal is to determine the appropriate empirical antibiotics for UTI patients visiting ER. Methods: This is a retrospective, chart-review study. Patients above 20 years old who visited our ER with UTI-related diagnosis and antibiotic treatments during March 1,2011 to May 31, 2011 were included. The prescription pattern, urine culture results, and sensitivity tests were recorded and analyzed. Clinical response rate as treatment outcome were evaluated at Day 3 (D3), Day 7 (D7) and end of therapy (EOT).Treatment outcomes were compared between patient groups with different empirical antibiotics, and between patient groups with appropriate and inappropriate empirical antibiotic use. The risk factors for treatment failure at D3 and cefazolin resistance were conducted by logistic regression. Results: Total 424 patients were included, with 242 patients stayed in ER for <48 hours and 182 patients stayed in ER for≧48 hours or admitted to wards. Among the 424 patients, 54% patients received first generation cephalosporins treatment and 19.3% patients received second generation cephalosporins treatment empirically. For patients stayed in ER for <48 hours, physicians frequently prescribed cephalexin for 3 days with the diagnosis of cystitis. For patients stayed in ER for≧48 hours or admitted to ward, physicians frequently prescribed cefazolin with the common diagnosis of acute pyelonephritis. However, physicians tended to upgrade antibiotics from cefazolin to other antibiotics due to presumed failure. In patients who were older or had complicated UTI, HCA UTI, chronic kidney disease, and suspected coinfections such as pneumonia and cellulitis, physicians tended to prescribe antibiotics other than cefazolin and cefmetazole. Escherichia coli was less common in HCA UTI patients than in CA UTI patients(41.0% vs 66.1%, p<0.0001), but Pseudomonas aeruginosa(16.7% vs 1.3%, p<0.0001) and yeast(5.1% vs 0.4%, p=0.0145) were more frequent in HCA UTI patients. Amoxicillin/clavulanate,cefmetazole, cefotaxime,gentamicin,cefepime, ceftazidime and levofloxacin resistance were more common in HCA UTI bacteruria . However, the treatment outcome at D3, D7 and EOT were not significantly different between CA UTI and HCA UTI patients. Regarding treatment outcome at D3, D7 and EOT, there were no significant differences between groups with different empirical antibiotics. In the subgroup analysis, there was a lower treatment successful rate at D3 when inappropriate empirical antibiotics were given (51.7% vs 76.4%, p=0.0215). Of patients with inappropriate empirical antibiotics, 70% had changed to another antibiotic according to urine culture sensitivity tests or clinical response. At D7 and EOT, the treatment outcomes were not different between patients received inappropriate empirical treatment and those received appropriate empirical treatment. Risk factors associated to D3 treatment failure were obstructive uropathy(OR=4.395, p=0.0129), inappropriate empirical antibiotic(OR=4.624, p=0.0126), and change in initial antimicrobial therapy for presumed failure within 3 days(OR=7.051,p<0.0001). Risk factors associated to cefazolin resistance were foreign instruments (OR=10.549, p=0.0223) and first generation cephaslosporins use within previous 1 month (Chi-square, p=0.0221). Conclusion: The results showed the treatment outcomes were not different between patient groups with different empirical antibiotics. For UTI patients presenting to ER, cefazolin as the empirical antibiotic is acceptable. Because inappropriate empirical antibiotics may lead to early treatment failure, if patients with risk factors for cefazolin-resistant pathogens, such as foreign instruments or previous use of first generation cephalosporin within 1 month, second generation cephalosporin may be an alternative choice if we want patients to get improved earlier. | en |
dc.description.provenance | Made available in DSpace on 2021-06-16T16:28:53Z (GMT). No. of bitstreams: 1 ntu-102-R99451003-1.pdf: 3528701 bytes, checksum: 8ba75f606648d4bcf3cd5916058441e1 (MD5) Previous issue date: 2013 | en |
dc.description.tableofcontents | 誌謝 i
中文摘要 ii Abstract v 目錄 viii 圖目錄 x 表目錄 xi 縮寫表 xiii 第1章 前言 1 第2章 文獻探討 3 2.1 流行病學 3 2.2 泌尿道感染之診斷與分類 3 2.3 致病菌種 5 2.4 治療準則 5 2.5 急診之泌尿道感染 10 2.6 抗藥性之趨勢與影響 14 2.7 社區型與醫療照護相關型泌尿道感染之差異 16 2.8 影響治療結果之因子 19 第3章 研究目的 24 第4章 研究方法 25 4.1 研究設計 25 4.2 研究之時間、地點與對象 28 4.3 資料收集 30 4.4 名詞定義 32 4.5 治療結果評估 37 4.6 統計分析 39 第5章 研究結果 40 5.1 收案流程 40 5.2 病人基本資料 43 5.3 急診醫師之處方型態 60 5.4 尿液培養結果 66 5.5 敏感性試驗結果 72 5.6 治療結果 75 5.7 危險因子分析 90 第6章 討論 99 6.1 泌尿道感染之族群 99 6.2 急診之處方型態 100 6.3 對各抗生素之敏感性試驗結果 102 6.4 社區型感染與醫療照護相關型感染之比較 105 6.5 治療結果 107 6.6 危險因子分析 110 6.7 研究限制 111 第7章 結論 113 第8章 參考文獻 115 附件 個案報告表 (Case report form) 121 | |
dc.language.iso | zh-TW | |
dc.title | 社區發作泌尿道感染病人之抗生素治療分析 | zh_TW |
dc.title | Retrospective study of antibiotics treatment for patients with community onset urinary tract infection | en |
dc.type | Thesis | |
dc.date.schoolyear | 101-1 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 林慧玲,林淑文,盛望徽,王振泰 | |
dc.subject.keyword | 泌尿道感染,急診,社區發作,經驗性抗生素,醫療照護相關型,治療結果, | zh_TW |
dc.subject.keyword | Urinary tract infection,emergency department,community-onset,empirical antibiotic,healthcare-associated,treatment outcome, | en |
dc.relation.page | 130 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2013-01-07 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 臨床藥學研究所 | zh_TW |
顯示於系所單位: | 臨床藥學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-102-1.pdf 目前未授權公開取用 | 3.45 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。